Alzheimer’s is already the most expensive disease in the United States, and its cost is growing steadily, so it's no great surprise that news of promising results from two monoclonal antibody drugs got a lot of attention last week, Tabitha M. Powledge writes. Too bad it wasn't right: "There are plenty of hard-nosed critiques out there, so it’s difficult to understand the media huzzahs. Unless so-called reporters are just swallowing press releases whole. Oh, wait …"
August 1, 2015
.png)
